Lupin Limited has informed the Exchange regarding a press release dated October 01, 2025, titled "Lupin Launches Rivaroxaban for Oral Suspension in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has launched Rivaroxaban for Oral Suspension in the US market, expanding its generic portfolio. Rivaroxaban is the generic equivalent of Bayer/Janssen's Xarelto, a widely used blood thinner (anticoagulant). The oral suspension form is particularly useful for patients who have difficulty swallowing tablets, such as children and the elderly. This launch follows the receipt of USFDA approval to market this formulation. The US is Lupin's largest market and generics launches like this typically contribute to steady base-business revenue growth.
Modestly positive for Lupin's US generics business as it adds another product in a high-demand therapeutic area. Likely a gradual revenue contributor rather than a sharp stock catalyst, since Rivaroxaban is a crowded generic market with multiple players.